Serum proteomic profiling reveals that pretreatment complement protein levels are predictive of esophageal cancer patient response to neoadjuvant chemoradiation

Annals of Surgery

Volumn 254, Issue 5, 2011, Pages 809-816

  Maher, Stephen G ^a   McDowell, Dermot T ^a   Collins, Ben C ^b   Muldoon, Cian ^a   Gallagher, William M ^b   Reynolds, John V ^a  

^a ST JAMES S HOSPITAL   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; APOLIPOPROTEIN A2; APOLIPOPROTEIN C3; CISPLATIN; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C4A; FLUOROURACIL; HAPTOGLOBIN;

ADULT; AGED; CANCER PATIENT; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COMPLEMENT BLOOD LEVEL; CONFERENCE PAPER; CONTROLLED STUDY; DRUG RESPONSE; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; FEMALE; HISTOPATHOLOGY; HUMAN; LYMPHADENECTOMY; MALE; MULTIMODALITY CANCER THERAPY; NEOADJUVANT CHEMORADIOTHERAPY; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION RESPONSE; SENSITIVITY AND SPECIFICITY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

ADULT; AGED; ALGORITHMS; BIOLOGICAL MARKERS; CHEMORADIOTHERAPY, ADJUVANT; COMPLEMENT C3A; COMPLEMENT C4A; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PROTEIN ARRAY ANALYSIS; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TREATMENT OUTCOME;

EID: 80255131121     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e31823699f2     Document Type: Conference Paper

References (45)

1. Fiorica F, Di Bona D, Schepis F, et al. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut. 2004;53: 925-930. (Pubitemid 38824146)
2. Gebski V, Burmeister B, Smithers BM, et al. Survival benefits from neoadju-vant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 2007;8:226-234. (Pubitemid 46291702)
3. Enzinger PC, Ilson DH. Irinotecan in esophageal cancer. Oncology (Williston Pa rk). 2000;14(suppl 14):26-30.
4. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349:2241-2252. (Pubitemid 37485141)
5. Portale G, Hagen JA, Peters JH, et al. Modern 5-year survival of resectable esophageal adenocarcinoma: single institution experience with 263 patients. J Am Coll Surg. 2006;202:588-596; discussion 596-598.
6. Reynolds JV, Muldoon C, Hollywood D, et al. Long-term outcomes following neoadjuvant chemoradiotherapy for esophageal cancer. Ann Surg. 2007;245:707-716. (Pubitemid 46684100)
7. Stahl M, Walz MK, Stuschke M, et al. Phase III comparison of preoper-ative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009;27:851-856.
8. Gaast AV, van Hagen P, Hulshof M, et al. Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: results from a multicenter randomized phase III study. J Clin Oncol. 2010;28:15s, abstract 4004.
9. Reynolds JV, Ravi N, Hollywood D, et al. Neoadjuvant chemoradiation may increase the risk of respiratory complications and sepsis after transthoracic esophagectomy. J Thorac Cardiovasc Surg. 2006;132:549-555. (Pubitemid 44278903)
10. Chirieac LR, Swisher SG, Ajani JA, et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer. 2005;103:1347-1355. (Pubitemid 40410728)
11. Walsh TN, Noonan N, Hollywood D, et al. Acomparisonofmultimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996;335:462-467. (Pubitemid 26269945)
12. Malik V, Lucey JA, Duffy GJ, et al. Early repeated 18F-FDG PET scans during neoadjuvant chemoradiation fail to predict histopathologic response or survival benefit in adenocarcinoma of the esophagus. J Nucl Med. 2010;51:1863-1869.
13. van Heijl M, Omloo JM, van Berge Henegouwen MI, et al. Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadju-vant chemoradiotherapy in patients with potentially curable esophageal cancer. Ann Surg. 253:56-63.
14. Luthra R, Wu TT, Luthra MG, et al. Gene expression profiling of localized esophageal carcinomas: association with pathologic response to preoperative chemoradiation. J Clin Oncol. 2006;24:259-267. (Pubitemid 46628468)
15. Maher SG, Gillham CM, Duggan SP, et al. Gene expression analysis of diagnostic biopsies predicts pathological response to neoadjuvant chemoradiother-apy of esophageal cancer. Ann Surg. 2009;250:729-737.
16. Liotta LA, Ferrari M, Petricoin E. Clinical proteomics: written in blood. Nature. 2003;425:905.
17. Conrads TP, Zhou M, Petricoin EF, III EF, et al. Cancer diagnosis using proteomic patterns. Expert Rev Mol Diagn. 2003;3:411-420. (Pubitemid 36859289)
18. Espina V, Dettloff KA, Cowherd S, et al. Use of proteomic analysis to monitor responses to biological therapies. Expert Opin Biol Ther. 2004;4:83-93. (Pubitemid 38057269)
19. Walshe L, Rowley S, Coffey M, et al. Comparison of two fractionation regimens in the multimodal therapy of cancer of the esophagus. Dis Esophagus. 2007;20:217-224. (Pubitemid 46831255)
20. Greene FL, Sobin LH. The TNM system: our language for cancer care. J Surg Oncol. 2002;80:119-120. (Pubitemid 34747614)
21. Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994;73:2680-2686. (Pubitemid 24166250)
22. Bradford MM. A rapid and sensitive method for the quantitation of micro-gram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
23. Tolson J, Bogumil R, Brunst E, et al. Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients. Lab Invest. 2004;84:845-856. (Pubitemid 38833244)
24. Miguet L, Bogumil R, Decloquement P, et al. Discovery and identification of potential biomarkers in a prospective study of chronic lymphoid malignancies using SELDI-TOF-MS. J Proteome Res. 2006;5:2258-2269. (Pubitemid 44330819)
25. Sundsten T, Eberhardson M, Goransson M, Bergsten P. The use of proteomics in identifying differentially expressed serum proteins in humans with type 2 diabetes. Proteome Sci. 2006;4:22.
26. de Bont JM, den Boer ML, Reddingius RE, et al. Identification of apolipopro-tein A-II in cerebrospinal fluid of pediatric brain tumor patients by protein expression profiling. Clin Chem. 2006;52:1501-1509. (Pubitemid 44148312)
27. Feng JT, Shang S, Beretta L. Proteomics for the early detection and treatment of hepatocellular carcinoma. Oncogene. 2006;25:3810-3817. (Pubitemid 43980476)
28. Smith FM, Gallagher WM, Fox E, et al. Combination of SELDI-TOF-MS and data mining provides early-stage response prediction for rectal tumors undergoing multimodal neoadjuvant therapy. Ann Surg. 2007;245:259-266. (Pubitemid 46151655)
29. Bollschweiler E, Metzger R, Drebber U, et al. Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis. Ann Oncol. 2009;20:231-238.
30. Geh JI, Bond SJ, Bentzen SM, et al. Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: evidence of a radiation and chemotherapy dose response. Radiother Oncol. 2006;78: 236-244.
31. Bollschweiler E, Holscher AH, Metzger R. Histologic tumor type and the rate of complete response after neoadjuvant therapy for esophageal cancer. Future Oncol. 2010;6:25-35.
32. Rosenzweig CN, Zhang Z, Sun X, et al. Predicting prostate cancer biochemical recurrence using a panel of serum proteomic biomarkers. J Urol. 2009;181:1407-1414.
33. Habermann JK, Roblick UJ, Luke BT, et al. Increased serum levels of complement C3a anaphylatoxin indicate the presence of colorectal tumors. Gastroen-terology. 2006;131:1020-1029; quiz 1284. (Pubitemid 44498688)
34. Gilliam BE, Wolff AE, Moore TL. Partial C4 deficiency in juvenile idiopathic arthritis patients. J Clin Rheumatol. 2007;13:256-260. (Pubitemid 47549162)
35. Yang Y, Chung EK, Zhou B, et al. The intricate role of complement component C4 in human systemic lupus erythematosus. Curr Dir Autoimmun. 2004;7: 98-132.
36. Franzke A, Peest D, Probst-Kepper M, et al. Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer. J Clin Oncol. 1999; 7:529-533. (Pubitemid 29075239)
37. Zafar GI, Grimm EA, Wei W, et al. Genetic deficiency of complement isoforms C4A or C4B predicts improved survival of metastatic renal cell carcinoma. J Urol. 2009;181:1028-1034; discussion 1034.
38. Hugli TE. Biochemistry and biology of anaphylatoxins. Complement. 1986;3:111-127. (Pubitemid 17208216)
39. Rutkowski MJ, Sughrue ME, Kane AJ, et al. Cancer and the complement cascade. Mol Cancer Res. 8:1453-1465.
40. Mantovani A. Molecular pathways linking inflammation and cancer. Curr Mol Med. 2010;10:369-373.
41. Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature. 2008;454:436-444.
42. Abdel-Latif MM, O'Riordan J, Windle HJ, et al. NF-kappaB activation in esophageal adenocarcinoma: relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy. Ann Surg. 2004;239:491-500. (Pubitemid 38372765)
43. Abdel-Latif MM, Duggan S, Reynolds JV, et al. Inflammation and esophageal carcinogenesis. Curr Opin Pharmacol. 2009;9:396-404.
44. Li J, Pircher PC, Schulman IG, Westin SK. Regulation of complement C3 expression by the bile acid receptor FXR. J Biol Chem. 2005;280: 7427-7434. (Pubitemid 40349633)
45. Pepe MS, Etzioni R, Feng Z, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst. 2001;93:1054-1061. (Pubitemid 32717537)